-
Mashup Score: 1Aditi Shastri, MD: Clinicians Needs to ‘Come Together’ on TP53-Mutated MDS | Blood Cancers Today - 4 day(s) ago
Using the VALIDATE database, researchers looked at treatment response to HMAs and overall survival in patients with TP53-mutated MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 14'The HemOnc Pulse' Live: Dr. Zeidan Talks MDS Panel, Other Exciting Sessions | Blood Cancers Today - 7 day(s) ago
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 14'The HemOnc Pulse' Live: Dr. Zeidan Talks MDS Panel, Other Exciting Sessions | Blood Cancers Today - 7 day(s) ago
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 8 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 18 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1How COVID-19 Helped Me Cope Day to Day With Cancer - 19 day(s) ago
I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 21 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 21 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
🎧 The newest episode of The HemOnc Pulse features @aditishasMD, a physician-scientist at @ae_cancercenter. Dr. Shastri discusses the latest news in #MDS and urges clinicians to "come together" to help patients with TP53 mutations. Check it out! ➡️ https://t.co/IcYxEuFCYJ https://t.co/jSXMsJduTT